Sample readiness
Tissue history, morphology, RNA quality and assay eligibility may live in separate records.
AH HealthTech ApS · Denmark
We build focused health technology that makes complex scientific and human decisions clearer, more accessible and more accountable.
AH Somics is our first official product and is currently at concept / pre-MVP stage.
Evidence review
Our first official product
From sample quality to biological insights. AH Somics is being developed to connect pre-assay readiness with downstream single-cell and spatial omics analysis.
Concept / pre-MVPTissue history, morphology, RNA quality and assay eligibility may live in separate records.
Run, library and imaging QC require protocol-specific scientific judgement.
Clustering, annotation and spatial analysis can become disconnected from upstream sample conditions.
Our hypothesis: laboratories need traceable, workflow-wide quality context—not another isolated dashboard.
The proposed solution
AH Somics is designed to connect upstream evidence, assay outcomes and biological interpretation while keeping scientists in control.
Tissue and cell samples, preparation history and assay metadata.
Morphology, RNA or cell QC and assay-aware checks.
Single-cell and spatial data through supported standard pipelines.
A joined quality record that keeps scientific context visible.
Concept architecture. Functions described here are planned and have not yet been implemented.
A focused starting point
Traceable, explainable quality decision support using versioned rules and human review.
Sample metadata, fixation and storage, H&E assessment, RNA quality or cell preparation metrics.
Assay-specific rules, missing-data flags, protocol compatibility and reviewer overrides.
Proceed / Review / Hold, evidence links and an exportable decision history.
Initial approach: rules plus human review. No predictive accuracy is claimed before validation.
Build on standard pipelines rather than reinventing them.
Innovation hypothesis
Connect sample provenance, preparation, QC evidence and later outcomes to each project.
Use modular, assay-specific checks and reusable schemas across supported platforms.
Show rationale, sources and uncertainty while scientists retain final sign-off.
The test: novelty remains unproven. Validation must demonstrate reduced review time, stronger decision consistency or another measurable benefit.
Who it is for
The initial buyer hypothesis centres on laboratory and facility managers responsible for quality, documentation and research workflows.
Shared single-cell and spatial services with repeatable QC needs.
Teams connecting sample preparation to biological interpretation.
Research groups that need controlled, auditable decision support.
Denmark offers a concentrated single-cell and spatial research ecosystem for founder-led discovery and local validation before broader Nordic and European expansion.
No institutional partnership, facility endorsement or customer relationship is claimed.AH HealthTech ApS
AH HealthTech ApS is a Danish health technology company developing focused digital products at the intersection of life science, decision support and human-centred design.
Make meaningful health technology clearer and more accessible.
AH Somics · currently in development.
Denmark
Open to research conversations
We welcome conversations with core facilities, translational laboratories and scientific workflow experts.
info@ahhealthtech.com